Brief: Morphosys Says Q1 Consolidated Loss At EUR 44.4 Mln Vs EUR 122.7 Mln Year Ago
May 3 (Reuters) - MorphoSys AG MORG.DE :
* Q1 GROUP REVENUES AT EUR 62.3 MILLION VERSUS EUR 41.5
MILLION
YEAR AGO
* Q1 OPERATING LOSS AT EUR 69.5 MILLION VERSUS EUR 68.0
MILLION
YEAR AGO
* Q1 COST OF SALES AT EUR 21.0 MILLION VERSUS EUR 7.9
MILLION YEAR
AGO
* Q1 COST OF SALES RELATED TO MONJUVI'S US PRODUCT SALES AT
EUR
3.1 MILLION
* Q1 CONSOLIDATED LOSS AT EUR 44.4 MILLION VERSUS EUR 122.7
MILLION YEAR AGO
Further company coverage: MORG.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Morphosys AG
See all newsBrief: Morphosys Announces Voluntary Delisting From The Nasdaq Global Market
Brief: Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00
Brief: Morphosys And Novartis Sign Delisting Agreement
Brief: Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders
Brief: Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO